As determined by the Australasian COVID-19 Trial (ASCOT), the optimal
dosage of anti-clotting medication for COVID-19 patients requiring
hospitalisation has been resolved. Thromboses, or blood clots, are more
common in hospitalised patients with COVID-19 and may play a role in the
eventual failure of vital organs. All of these people are going to be given
blood-thinning drugs.
dosage of anti-clotting medication for COVID-19 patients requiring
hospitalisation has been resolved. Thromboses, or blood clots, are more
common in hospitalised patients with COVID-19 and may play a role in the
eventual failure of vital organs. All of these people are going to be given
blood-thinning drugs.
More than 1,500 patients in Australia, New Zealand, India, and Nepal
participated in a randomised clinical trial of different doses of
anti-clotting medicine led by the ASCOT team, which included Professors
Bala Venkatesh and Vivek Jha from The George Institute.
